SCHEMBL796022

SCHEMBL796022

CN(c1ccccc1)c1nc(N)nc(-c2noc(N3CCC(OCc4ccccc4)CC3)n2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 2/20 0.38
PRMT6 Q96LA8 2/20 0.38
TMEM97 Q5BJF2 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
PRMT8 Q9NR22 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
OPRM1 P35372 2/20 0.35
OPRL1 P41146 2/20 0.35
POLB P06746 1/20 0.34
ALDH1A1 P00352 3/20 0.34
LMNA P02545 2/20 0.34
BCHE P06276 1/20 0.34
MAPK1 P28482 1/20 0.34
SCN9A Q15858 3/20 0.34
HRH4 Q9H3N8 1/20 0.33
RPS6KB1 P23443 1/20 0.33
USP2 O75604 1/20 0.33
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL808339 0.88 L3MBTL1 (0.37) L3MBTL1POLBALDH1A1LMNAUSP2
SCHEMBL796007 0.86 L3MBTL1 (0.39) CARM1PRMT6L3MBTL1POLBALDH1A1
SCHEMBL796187 0.86 L3MBTL1 (0.37) L3MBTL1POLBALDH1A1LMNAUSP2
Hydrochloric Acid SCHEMBL17220461 0.84 L3MBTL1 (0.42) L3MBTL1POLBALDH1A1LMNAHRH4
SCHEMBL796506 0.84 L3MBTL1 (0.42) L3MBTL1POLBALDH1A1LMNAUSP2
SCHEMBL795864 0.84 L3MBTL1 (0.39) L3MBTL1POLBALDH1A1LMNAUSP2
SCHEMBL795654 0.84 L3MBTL1 (0.39) L3MBTL1POLBALDH1A1LMNANPSR1
SCHEMBL796566 0.83 L3MBTL1 (0.41) HRH3L3MBTL1POLBALDH1A1LMNA
SCHEMBL796262 0.83 ACACB (0.39) L3MBTL1POLBALDH1A1NPSR1
SCHEMBL794854 0.83 ACACB (0.39) L3MBTL1POLBALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616465-B1 TRIAZINE-OXADIAZOLES NOVARTIS AG (CH) 2015-11-04 EP disclosed
EP-2616465-B1 TRIAZINE-OXADIAZOLES NOVARTIS AG (CH) 2015-11-04 EP disclosed
US-20150025057-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2015-01-22 US disclosed
US-20150025057-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2015-01-22 US disclosed
US-20150025057-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2015-01-22 US disclosed
US-8895733-B2 Triazine-oxadiazoles NOVARTIS AG (CH) 2014-11-25 US disclosed
US-8895733-B2 Triazine-oxadiazoles NOVARTIS AG (CH) 2014-11-25 US disclosed
US-8895733-B2 Triazine-oxadiazoles NOVARTIS AG (CH) 2014-11-25 US disclosed
US-20140051676-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2014-02-20 US disclosed
US-20140051676-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2014-02-20 US disclosed
US-20140051676-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2014-02-20 US disclosed
EP-2616465-A1 TRIAZINE-OXADIAZOLES Novartis AG (CH) 2013-07-24 EP disclosed
WO-2012035023-A1 TRIAZINE-OXADIAZOLES NOVARTIS AG (CH) 2012-03-22 WO disclosed
WO-2012035023-A1 TRIAZINE-OXADIAZOLES NOVARTIS AG (CH) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025057-A1 Triazine-oxadiazoles OPRK1, OPRD1, OPRL1 CARM1 3848/4885PRMT6 3332/4885TMEM97 1158/4885
US-20140051676-A1 Triazine-oxadiazoles OPRK1, OPRD1, OPRL1 CARM1 3848/4885PRMT6 3332/4885TMEM97 1158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.